Skip to main content

Frontiers of Engineering Reports on Leading-Edge Engineering from the 2016 Symposium (2017) / Chapter Skim
Currently Skimming:

Engineered Proteins for Visualizing and Treating Cancer - Jennifer R. Cochran
Pages 101-106

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 101...
... Important deliverables of this work include insight into ligand-mediated cell surface receptor interactions that drive disease, and the development of new protein-based drugs and imaging agents for translation to the clinic. BACKGROUND As the field of protein engineering evolved during the 1980s, modified proteins soon joined recombinant versions of natural proteins as a major class of new therapeutics.
Read the entire page →
From page 102...
... CURRENT CHALLENGES Challenges for cancer therapeutics include the need for more selective localization to tumors versus healthy tissue, and improved tissue penetration and delivery to brain tumors, which are protected by the restrictive blood-brain barrier. Other therapeutic challenges are tumor heterogeneity that makes cancers difficult to treat, acquired drug resistance that cannot be overcome because of dose limiting drug toxicity, and lack of effective drugs to treat cancer once it has spread.
Read the entire page →
From page 103...
... Moreover, Gas6 binding affinity was critical and correlative with the ability of decoy receptors to effectively inhibit metastasis and disease progression. The engineered Axl decoy receptor inhibited up to 90 percent of metastatic nodules in two murine models of ovarian cancer compared to wild-type Axl (~50 percent inhibition)
Read the entire page →
From page 104...
... . We then showed that intravenous injection of an engineered knottin, conjugated to a near-infrared fluorescent dye molecule, targeted and illuminated intracranial brain tumors in animal models of medulloblastoma (collaborations with Matthew Scott, Stanford Developmental Biology, and Samuel Cheshier and Gerald Grant, Stanford Neurosurgery)
Read the entire page →
From page 105...
... CONCLUSIONS Research and development efforts over the past few decades have culminated in a growing number of FDA-approved protein therapeutics that enable targeted treatment of cancer. In parallel, continued efforts to develop safer and more effective cancer therapeutics are being fueled by expanding knowledge of mechanisms underlying disease pathophysiology and the ability to customize proteins using a variety of engineering methods.
Read the entire page →
From page 106...
... Cancer Research 69:2435–2442. Kintzing JR, Cochran JR.
Read the entire page →

Key Terms

  • engineered axl
  • protein therapeutics
  • knottin peptide
  • engineered protein
  • axl decoy

  • decoy receptor
  • cancer therapeutics
  • tumor targeting
  • brain tumors
  • engineered cystine

  • engineered peptides
  • protein engineering
  • metastatic disease
  • brain tumor
  • disease pathophysiology

  • effective drugs
  • underlying disease
  • molecular imaging
  • axl receptor
  • animal models

  • protein design
  • slac national
  • structural alterations
  • targeted drug
  • protein therapeutic

  • receptor tyrosine
  • cystine knot
  • national accelerator
  • drug delivery
  • imaging agents


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.